Home / Organizations / Biogen

Biogen

Biogen is one of the world’s leading biotechnology companies headquartered in Cambridge, Massachusetts, USA. Biogen was started with a focus on developing therapies for neurodegenerative, hematologic and autoimmune disorders. Founded in 1978, their work in biologics and small-molecule drug discovery has been so impressive leading to world’s most extensive portfolio of multiple sclerosis therapies and innovative new treatments for hemophilia patients. Company’s advanced research programs include exploration of potential candidates for serious and difficult-to-treat neurodegenerative diseases and fibrotic and nonmalignant blood disorders.

In 2014, Biogen was named the global biotechnology industry leader on the Dow Jones Sustainability World Index, appearing on the list for the fifth consecutive year as one of only two biotechnology companies included, and, in 2015, the Corporate Knights ranked Biogen as the most sustainable company in the world. Today, Biogen is one of the oldest independent biotechnology companies in the world.

Product Portfolio:

  • Alprolix
  • Avonex
  • Eloctate
  • Fampyra
  • Gazyva
  • Plegridy
  • Rituxan
  • Tecfidera
  • Tysabri

Company Information

Type Public company
Traded as NASDAQ: BIIB
Industry Biotechnology
Founded 1978
Founder Phillip Allen Sharp
Headquarters Cambridge, MA, USA
Key people Stelios Papadopoulos, Chairman
George A. Scangos, CEO
Products Alprolix, Avonex, Eloctate, Fampyra, Gazyva*, Plegridy, Rituxan*, Tecfidera, Tysabri
Revenue US$ 9.703 billion (2014)
Net income US$ 2.941 billion (2014)
Number of employees 7,550 (December 2014)
Subsidiaries NA
Website www.biogen.com

Check Also

Valeant Pharmaceuticals

Valeant Pharmaceuticals is a publicly traded pharmaceutical company based in Montreal, Canada. The company has …